Shares of Intuitive Surgical (ISRG -0.55%) popped over 10% yesterday, after receiving great news that the FDA approved its new version of its surgical robot, the da Vinci Xi.
In this video, Motley Fool health-care analyst David Williamson looks through the various ways the Xi is superior to the previous model, the Si, and how those improvements could be a real catalyst for the stock going forward. David highlights the difficulties the stock has seen recently, from famed short-selling blog Citron Research's coming out with a bearish report on the company, to potential safety concerns cropping up. David also mentions that while he still sees Intuitive Surgical as the best pure play in robotic surgery, he does potentially still have some concerns.
